Vulvovaginal candidas during pregnancy (featires of the therapy in the first trimester)
- Authors: Borovikov I.O.1, Kutsenko I.I.1, Ermolaeva A.S.2
-
Affiliations:
- Kuban state medical university
- I.M. Sechenov First Moscow State Medical University
- Issue: No 5 (2018)
- Pages: 116-121
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248219
- DOI: https://doi.org/10.18565/aig.2018.5.116-121
- ID: 248219
Cite item
Open Access
Access granted
Abstract
Objective. Evaluation method of therapy for pregnant women, with vulvovaginal candidiasis, with a combination of oral and intravaginal introduction polyene macrolide - natamycin. Subjects and methods. The results of treatment in 110 pregnant women, patients with invasive vulvovaginal 10-12 weeks gestation: group 1 (n = 55) therapy with natamycin intravaginal at a dose of 100 mg 1 times daily for 6 days; Group 2 (n = 55) had combined treatment natamicinum intravaginal at a dose of100 mg 1 times daily for 6 days + natamicinum peroral at a dose of100 mg 4 times daily for 10 days. Direct microscopy, measuring the pH of the vagina, cultural method was using. Results. Found that the combined intake of natamicinum (oral and intravaginal reception) increases the clinical efficacy of therapy vulvovaginal candidiasis in 1.7 ± 0.12, and microbiological -1.3 ± 0.1 times. Conclusion. Application of combined therapy antimycotics reasonable etiologically (simultaneous vaginal disinfection and colon) with polyene macrolides natamycin has the fewest side effects, absence of adverse effects on the fetus, and helps improve clinical microbiological efficacy of treatment in patients vulvovaginal invasive.
Full Text
About the authors
Igor O. Borovikov
Kuban state medical university
Email: bio2302@gmail.com
MD, PhD, Department of Obstetrics and Gynecology
Irina I. Kutsenko
Kuban state medical universityMD, Professor, Head of Department of Obstetrics and Gynecology
Anna Savvichna Ermolaeva
I.M. Sechenov First Moscow State Medical UniversityPh.D., Associate Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
References
- Серов В.Н., Тютюнник В.Л. Вульвовагинальный кандидоз: особенности течения и принципы лечения. Фарматека. 2015; 15: 38-43.
- Тютюнник В.Л., Карапетян Т.Э., Балушкина А.А. Современные принципы профилактики и лечения вульвовагинального кандидоза. Русский медицинский журнал. 2010; 18(19): 1186-90.
- Chatwani A., Mehta R., Hassan S. Rapid testing for vaginal yeast detection: a prospective study. Am. J. Obstet. Gynecol. 2012; 196(4): 309-14.
- Прилепская В.Н., Байрамова Г.Р. Вульвовагинальный кандидоз. Клиника, диагностика, принципы терапии. М.: ГЭОТАР-Медиа; 2010. 80с.
- Малова И.О., Петрунин Д.Д. Натамицин - противогрибковое средство класса полиеновых макролидов с необычными свойствами. Вестник дерматологии и венерологи. 2015; 3: 161-84.
- Kennedy M., Sobel J. Vulvovaginal сandidiasis сaused by non-albicans Candida species: new insights. Curr. Infect. Dis. Rep. 2013; 12(6): 465-70.
- Fülagas M., Betsi G., Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J. Antimicrob. Chemother. 2011; 58(2): 266-72.
- Stock I. Fungal diseases of vulva and vagina caused by Candida species. Med. Monatsschr. Pharm. 2010; 33(9): 324-33.
- Арзуманян В., Мальбахова Е.Т., Магаршак О.О., Осокина О.В. Мониторинг эффективности натамицина и азолов in vitro по отношению к штаммам дрожжевых грибов, выделенных с разных типов эпителия. Вопросы гинекологии, акушерства и перинатологии. 2015; 14(4): 58-63.
- Мозговая Е.В., Талалаева Н.Е., Маругина Е.А., Рыбина Е.В. Антимикотическая терапия кандидозного вульвовагинита у беременных. Доктор.Ру. 2014; 8(ч.1): 57-63.
- Kauffman C., Pappas P., Sobel J., Dismukes W., eds. Essentials of clinical mycology. 2nd ed. New York: Springer; 2016.
- Gonçalves B., Ferreira C., Alves C.T., Henriques M., Azeredo J., Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 2016; 42(6): 905-27.
- Карась И.Ю., Гришакова В.А., Равинг Л.С., Карась Д.В., Красильникова К.С. Вагинальный кандидоз - медико-социальные, психологические и этиологические аспекты. Мать и дитя в Кузбассе. 2006; 2: 32-4.
- Ehrstrom S., Kornfeld D., Rylander E. Perceived stress in women with recurrent vulvovaginal candidiasis. J. Psychosom. Obstet. Gynaecol. 2007; 28(3): 169-76.
- Малова И.О., Кузнецова Ю.А. Современные особенности клинического течения урогенитального кандидоза и анализ антимикотической чувствительности грибов рода Candida. Вестник дерматологии и венерологии. 2015; 2: 68-75.
- Jobst D., Kraft K. Candida species in stool, symptoms and complaints in general practice - a cross-sectional study of 308 outpatients. Mycoses. 2006; 49(5): 415-20.
- Czeizel A.E., Kazy Z., Vargha P. A case-control teratological study of vaginal natamycin treatment during pregnancy. Reprod. Toxicol. 2003; 17(4): 387-91.
- Levinskas G.J., Ribelin W.E., Shaffer C.B. Acute and chronic toxicity of pimari-cin. Toxicol. Appl. Pharmacol. 1966; 8(1): 97-109.
Supplementary files
